StemRIM (TYO:4599)

Japan flag Japan · Delayed Price · Currency is JPY
251.00
-2.00 (-0.79%)
Dec 17, 2025, 11:14 AM JST
-23.48%
Market Cap15.72B
Revenue (ttm)n/a
Net Income (ttm)-1.90B
Shares Out62.14M
EPS (ttm)-30.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume38,000
Average Volume108,980
Open251.00
Previous Close253.00
Day's Range248.00 - 252.00
52-Week Range246.00 - 370.00
Beta0.87
RSI37.36
Earnings DateDec 10, 2025

About StemRIM

StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene thera... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 45
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4599
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.